Preparing for Long-acting Injectable antiretroviral therapy for HIV in Los Angeles

Presenter:

Oluwadamilola Jolayemi, MSc Program Coordinator, UCLA CHIPTS

Study Team

Laura Bogart, PhD Rebecca Cohen, MD, MPH David Goodman-Meza, MD, MAS Oluwadamilola Jolayemi, MSc Raphael Landovitz, MD, MSc Elena Rosenberg-Carlson, MPH Steve Shoptaw, PhD Erik Storholm, PhD





Long Acting Injectable for HIV Treatment

- Current treatment is daily oral antiretroviral therapy
- Received regulatory approvals in US
- Requires monthly clinic visits for injection
 - Potentially every 2 months pending regulatory approvals
 - Possible burden health care delivery systems
- Must be virally suppressed prior to initiation
 - Possible gaps in access

Study Goals



Strengthen and develop partnerships and build capacity in partners to support research on implementation of LAI ART for HIV as part of a strategy to optimize viral suppression in Los Angeles County Assess the policy, systems, financial, operational and clinical level barriers to and facilitators of the rollout and scale-up of LAI ART in Los Angeles County Assess the end-user (consumer) perceived barriers to and facilitators of LAI ART use in Los Angeles County

Qualitative Methods

5 focus groups/interviews

- 2 consumer focus groups
- 1 clinical provider focus group
- 1 clinical/non-clinical provider focus group
- 1 semi-structured interview session (non-clinical)

Participants

- 18 consumer stakeholders
- 23 clinical and nonclinical stakeholders

Location-Los Angeles County

Characteristics of participants

Consumer Participants n=18		Clinical and Non-clinical Participants n=23	
Age M (SD) Range	52.2 (11.5), 20-69 years	Age M (SD) Range	45.65 (12.47), 28-75 years
Cisgender male n (%) Cisgender female n (%)	13 (72) 5 (28)	Cisgender male n (%) Cisgender female n (%)	17 (74) 6 (26)
Sexual orientation n (%) Bisexual Gay/Lesbian (homosexual) Straight (heterosexual)	3 (17) 11 (61) 4 (22)	Roles n, (%) Clinical provider Non-clinical provider Unreported	14 (61) 8 (35) 1 (4)
Race/Ethnicity n (%) Black (Non-Hispanic/Latinx) Hispanic/Latinx White (Non-Hispanic/Latinx)	7 (39) 9 (50) 2 (11)	Race/Ethnicity n (%) Asian (Non-Hispanic/Latinx) Black (Non-Hispanic/Latinx) Hispanic/Latinx White (Non-Hispanic/Latinx)	4 (17) 8 (35) 6 (26) 5 (22)

Findings

X

General perspectives

Overall enthusiasm and acceptance for LAI ART as a new treatment option

"**new tool in the toolbox**" of HIV treatment options



Consumer level considerations

Key facilitators and barriers

Organizational level considerations Key facilitators and barriers



Messaging Recommendations

Implementation Recommendations

"Well, I think it's a positive contributor to our materials to treat our patients. It's not going to be with every patient, but there will [be] patients that it will be their ideal treatment." (Clinical stakeholder)

"I think that that would be so awesome when that gets approved because for me, I would prefer to do a long acting injectable instead of having to take a pill every day..." (Consumer)

CHIPTS 2021 HIV Next Generation Conference 6

	Adherence and Resistance	Treatment Management Burden	
erations entation- her level	Medical Mistrust	Stigma	
	Pain, Side Effects and Comfort with Shots		

Кеу conside for impleme Consum

Illustrative Quotes

• Stigma

"A lot of patients we find just the daily routine of taking a pill every day is a reminder that they are ill, and I think the injectable has an option to take that stigma away, or at least [take] that personal, internal stigma away from those people living with HIV, who kind of feel that burden." (Clinical stakeholder)

Medical Mistrust

"That is actually a huge thing in the Black community. Mistrust or a lack of trust in the healthcare field...So that could definitely be an issue that could get in the way..." (Consumer)

Key considerations for implementation - Organizational

level



Illustrative Quotes


• Provider Preparedness

"...I think implementing the program for injectables of HIV clinics has to be very well thought in regard to training and capacity building. Not only from the clinic administrators, but also from the persons dispensing and applying the medications." (Non-clinical stakeholder)

• Staff capacity

"...You're talking about an influx actually of new visits potentially. Whether our clinics can handle that, whether we have the staffing..." (Non-clinical stakeholder)

Key recommendations



Messaging recommendations

Community engagement in development and delivery

Mode of messaging-TV, billboards, social media, presentations

Trusted sources of information

Messaging types-simple messages highlighting benefits of LAI ART



Implementation recommendations

Alternative staff to deliver LAI ART treatment Treatment education and adherence support Research trials and demonstration project Innovative implementation strategies

"...the peer-to-peer strategy. I think [it] is incredibly effective, particularly when using people within a community ...You tell them, 'Hey, we've got this. Could you talk to your friends and stuff about it?' I think when they're the ones to push the message, especially for people of color, then it's a little more digestible." (Non-clinical stakeholder)

Recommended Next Steps

- Partnership building, seamless coordination and effective communication across stakeholders on the public and private level
- Establishing seamless systems within HIV service delivery organizations (specifically addressing implementation barriers)
- Establishing policies and standardized treatment guidelines and protocols around LAI ART for HIV
- Ensure that LAI ART for HIV is included in insurance formularies

Ending the HIV Epidemic Planning Project Collaborators

- LA County DHSP
- RAND Corporation
- UCLA
- CHIPTS Community Advisory Board
- Funding: National Institute of Mental Health (NIMH P30MH058107)
- Thank you to the study participants from Los Angeles community and various partner organizations.

Thank you for listening!

Questions?